Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06560294
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
Glue Embolization vs Conservative Treatment for Pelvic Congestion Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Glue Embolization Versus Conservative Treatment for Pelvic Congestion Syndrome A Randomized Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to compare glue embolization and conservative treatment for pelvic congestion syndrome regarding safety and efficacy
Detailed Description:
Pelvic congestion syndrome PCS is a common cause of chronic lower abdominalpelvic pain estimated to affect about 40 of women predominantly between the ages of 30 and 45The treatment of PCS depends mainly on the severity of the pain Non-steroid anti-inflammatory drugs are often used and contraceptives have a role in cases of pain associated predominantly with menstruation
Traditionally conservative approaches such as pharmacotherapy with venoactive drugs like micronized purified flavonoid fraction Daflon have been utilized to address the symptoms of PCS Daflon has been used to treat venous insufficiency and has demonstrated efficacy in reducing symptoms and improving the quality of life in patients with PCS Its mechanism of action includes improving venous tone reducing venous stasis and exerting anti-inflammatory effects Endovascular treatment of PCS is challenging and requires occlusion of incompetent pelvic veins
Traditionally conservative approaches such as pharmacotherapy with venoactive drugs like micronized purified flavonoid fraction Daflon have been utilized to address the symptoms of PCS Daflon has been used to treat venous insufficiency and has demonstrated efficacy in reducing symptoms and improving the quality of life in patients with PCS Its mechanism of action includes improving venous tone reducing venous stasis and exerting anti-inflammatory effects Endovascular treatment of PCS is challenging and requires occlusion of incompetent pelvic veins
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None